Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | CCKAR | P32238 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | GHSR | Q92847 | 1/20 | 0.71 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.71 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300966 | 1.00 | UGT1A1 (0.71) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL30018952 | 1.00 | UGT1A1 (0.71) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL2175950 | 1.00 | UGT1A1 (0.71) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL16298849 | 0.97 | UGT1A1 (0.73) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL2178325 | 0.97 | UGT1A1 (0.69) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL10034686 | 0.96 | UGT1A1 (0.69) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL8224259 | 0.95 | UGT1A1 (0.66) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL893599 | 0.94 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL16866221 | 0.93 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6157358 | 0.93 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382207-B2 | Process for the preparation of atazanavir bisulfate | LAURUS LABS PRIVATE LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| EP-2522367-B1 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9107956-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-18 | — | — | US | disclosed |
| US-9095620-B2 | Reagents | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150183742-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE | LAURUS LABS LIMITED (IN) | 2015-07-02 | — | — | US | disclosed |
| EP-2262538-B1 | OLIGOMER-AMINO ACID CONJUGATE | NEKTAR THERAPEUTICS (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140045770-A1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2522367-A1 | Oligomer-protease inhibitor conjugates | Nektar Therapeutics (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100184989-A1 | De Novo Synthesis of Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2008112286-A9 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS AL CORP (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184989-A1 | De Novo Synthesis of Conjugates | ABCG2, UGT1A8, SLC7A5 | UGT1A1 7/4885MLNR 367/4885NR1I2 2182/4885 |
| US-20150183742-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE | SAMHD1, CYP3A4, APOBEC3C | UGT1A1 76/4885MLNR 3471/4885NR1I2 3470/4885 |
| US-20140045770-A1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | DNPEP, ADAM17, SERPINB1 | UGT1A1 650/4885MLNR 302/4885NR1I2 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.